Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera®) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

NCT05987176 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT05987176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05987176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera®) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
Lead sponsor
Imperial College London
Phase
Phase 2
Overall status
Terminated
Start date
August 2, 2024
Completion date
October 21, 2025
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine neoplasm, gastroenteropancreatic neuroendocrine tumor, liver metastases, neuroendocrine tumor g1 (net g1)/carcinoid, neuroendocrine tumor grade 2, neuroendocrine tumors